drugset / Trial / NCT01978496

Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

NCT01978496

Phase 3 Completed 1334 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.

Timeline

Start
1996-07
Primary completion
1997-12
Completion
1997-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eletriptan Small molecule 20 mg Oral
Subject Eletriptan Small molecule 40 mg Oral
Subject Eletriptan Small molecule 80 mg Oral

Indications